This site is intended for health professionals only!

Published on 21 February 2013

Share this story:

ARIAD announces appointments

teaser

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) has announced the appointment of Jonathan E Dickinson to the position of General Manager, ARIAD Pharmaceuticals (Europe), Sàrl.
Mr Dickinson is a seasoned commercial executive bringing more than 20 years of pharmaceutical-industry experience to ARIAD, with special emphasis on global and pan-European leadership of several important cancer medicines. Mr Dickinson is responsible for leading ARIAD’s European commercialisation initiatives –focused first on the anticipated European approval and launch of Iclusig® (ponatinib) in the third quarter of 2013 and subsequently on ARIAD’s other cancer medicines in development.
Mr Dickinson joined ARIAD from Bristol-Myers Squibb, where he served for the past three years as the European brand lead for ipilimumab, responsible for the product’s European launch and commercialisation in 29 countries.  Previously, during his 13-year tenure at Hoffmann-La Roche, Mr Dickinson held several key leadership positions, including lifecycle leader for capecitabine, where he managed global marketing, clinical development, regulatory affairs and manufacturing activities for the brand.  At Roche, he had assignments both in the US and Switzerland that included leadership roles of Roche’s three leading oncology medicines — trastuzumab, rituximab, and capecitabine. Mr Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom.
Mr. Dickinson received his BSc degree in Genetics and his MBA degree from the University of Nottingham.  He is based at ARIAD’s European headquarters in Lausanne, Switzerland and reports to Marty J Duvall, senior vice president, commercial operations of ARIAD.
“Jonathan is a proven leader with broad commercial and general management experience promoting several of the most highly regarded oncology medicines available today,” stated Harvey J Berger, MD, chairman and chief executive officer of ARIAD. “His knowledge of the evolving European market and his success in commercialising important cancer medicines throughout Europe and globally will serve us well as we prepare for anticipated approval and commercialisation of Iclusig in the EU this year.”
Other key European appointments
Anna Casse – Head, Marketing and Sales. Ms Casse joined ARIAD from Novartis, where she served as head of the nephrology business unit in Germany.  Prior to this, as head of oncology marketing in Germany, she led the country launches of nilotinib and everolimus. Ms Casse also served as head of the Novartis oncology business in Finland and oversaw global business development and licensing for Novartis Opthalmics.  Prior to her eight-year tenure at Novartis, she spent four years in business development and strategic planning at Amgen Europe. She also worked as a consultant at Arthur Little in the Benelux countries. Ms Casse has a BS from the University of Birmingham and an MBA at the INSEAD, Fontainebleau, France.
Anant Murthy, PhD – Head, Pricing, Reimbursement and Access.  Dr Murthy joined ARIAD from Celgene, where he was most recently the executive director and head of global pricing and market access for haematology and oncology.  Previously, he expanded and led Celgene’s European pricing team to support the launches of lenalidomide, azacitidine, and nab-paclitaxel across the EMEA region. Prior to Celgene, Dr Murthy worked in the reimbursement and health economics team for the CRDM business of Medtronic, Inc. Dr Murthy has a BA from the University of Rochester, an MS in international health economics from the London School of Economics, and a PhD in international health systems from the Johns Hopkins Bloomberg School of Public Health.
Kai C. Chan, MD – Head, Medical Affairs. Dr. Chan joined ARIAD from Genzyme (Sanofi), where he was European head of medical affairs for transplant oncology. Previously, Dr. Chan was with Johnson and Johnson as global medical lead for bortezomib lung- cancer development, and with AstraZeneca in oncology clinical research. Dr Chan is a practicing surgeon at Wycombe Hospital in High Wycombe, UK Dr Chan has a MB, ChB, MD, and MSc in Oncology from the University of Manchester, a FRCS from the Royal College of Surgeons of Edinburgh, and a Diploma in Pharmaceutical Medicine from the University of Wales.
Thierry Bataillard – Head, Regulatory Affairs. Mr Bataillard joined ARIAD from Merck Serono, where he held leadership positions in regulatory affairs within the oncology, endocrinology and diabetes businesses. He has a MSc from the Institute of Industrial Pharmacy at the University of Bordeaux and a PharmD from Claude Bernard University.
ARIAD has also hired the country managers for France, Germany, Italy and the UK. Each of them brings over a decade of experience commercialising cancer medicines.
“As we build an integrated global oncology company, the recruitment of this outstanding European team clearly demonstrates our commitment to success,” stated Marty J Duvall, senior vice president, commercial operations of ARIAD.  “Led by Jonathan Dickinson, ARIAD will be fully prepared for the anticipated EU approval and launch of Iclusig later this year.”


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: